Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.
暂无分享,去创建一个
S. Rosenberg | R. Morgan | P. Robbins | M. El-Gamil | C. Cohen | Steven A Rosenberg | Richard A Morgan | Cyrille J Cohen | Yong F Li | Mona El-Gamil | Paul F Robbins
[1] R. Hagedoorn,et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. , 2007, Blood.
[2] S. Rosenberg,et al. Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1 , 2006, The Journal of Immunology.
[3] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[4] Yangbing Zhao,et al. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. , 2006, Cancer research.
[5] S. Rosenberg,et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] S. Rosenberg,et al. Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR , 2005, The Journal of Immunology.
[7] M. Nishimura,et al. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. , 2005, Cancer research.
[8] Meir Glick,et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. , 2003, Protein engineering.
[9] P. Greenberg,et al. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. , 2002, The Journal of clinical investigation.
[10] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[11] P. Greenberg,et al. Adoptive therapy with CD8 + T cells , 2002 .
[12] Hans J. Stauss,et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.
[13] C. Janeway,et al. Maintenance of TCR clonality in T cells expressing genes for two TCR heterodimers , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] N. Manolios,et al. The Interchain Disulfide Linkage of T-Cell Antigen Receptor-α and -β Chains Is a Prerequisite for T-Cell Activation , 1998 .
[15] Z. Li,et al. The interchain disulfide linkage of T-cell antigen receptor-alpha and -beta chains is a prerequisite for T-cell activation. , 1998, Cellular immunology.
[16] S. Caspar-Bauguil,et al. The interchain disulfide bond between TCR alpha beta heterodimers on human T cells is not required for TCR-CD3 membrane expression and signal transduction. , 1997, International immunology.
[17] H. Reid,et al. Cyclosporin A abrogates the acquired immunity to cutaneous reinfection with the parapoxvirus orf virus , 1996, Immunology.
[18] Z. Li,et al. Structural mutations in the constant region of the T-cell antigen receptor (TCR)beta chain and their effect on TCR alpha and beta chain interaction. , 1996, Immunology.
[19] Antonio Lanzavecchia,et al. T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.
[20] S. Rosenberg,et al. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.